<\/p>\n
On May 20, the Verkhovna Rada appointed Viktor Liashko as the new Minister of Health. The European Business Association congratulates Mr. Liashko on his appointment and hopes for fruitful and effective cooperation in building a strong healthcare system in the country. We also wish the Minister much inspiration in such interesting but difficult work.<\/span><\/p>\n The EBA community indicates <\/span>6 priority steps<\/span><\/strong>\u00a0that business expects from the new Minister.<\/span><\/p>\n First<\/span><\/strong>\u00a0is continuing and further intensification of work on overcoming the COVID-19 pandemic. In this context, it is critical to ensure that all citizens of Ukraine have access to the COVID-19 vaccine as soon as possible. This will require the coordinated work of the Ministry of Health of Ukraine, the Verkhovna Rada, and the pharmaceutical community, namely, in continuing the improvement of the current legal regulation accordingly to such challenges.<\/span><\/p>\n Second<\/span><\/strong>\u00a0is defining a clear strategy and plan for implementing the next steps in reforming Ukraine’s health care system, including at the level of secondary (specialized) and tertiary (highly specialized) medical care, further expanding the program of medical guarantees and reimbursements, taking into account modern approaches to the treatment of relevant diseases in the countries that Ukraine has identified as a reference; preventing the deterioration in the quality of medical services due to the inability to purchase the necessary drugs within the program of medical guarantees.<\/span><\/p>\n Third<\/span><\/strong>\u00a0is harmonizing Ukrainian legislation with EU legislation in the field of pharmaceuticals, medical devices, and clinical research, as well as ensuring the effective implementation of new practices for Ukraine – in particular, continuing to implement the medical technology assessment (MTA), creating an independent MTA Agency, assisting the completion of the optimal regulatory framework for the implementation of managed entry agreements, introducing “positive list” of drugs, introducing gradual 2D-code individual labeling with the use of EU experience.<\/span><\/p>\n Fourth<\/span><\/strong>\u00a0is digitalizing the health and pharmaceutical sectors to improve health care delivery, as well as discussing with business on drug registration, certification, and control procedures, primarily through the introduction of an eCTD registration format for drug and clinical trials materials.<\/span><\/p>\n